Filing Flows › Avalo Therapeutics (AVTX) › Q4 2024
Avalo Therapeutics (AVTX) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 20, 2025
Avalo Therapeutics (AVTX) reported revenue of $192K for the fourth quarter 2024 (Q4 2024), -66% from a year earlier and -23% from the quarter before.
Avalo Therapeutics, Q4 2024: revenue $192K (-66% year over year), net loss $35.3M, operating cash flow −$15.0M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $192K | -23% | -66% |
| Operating profit | −$13.3M | — | — |
| Net earnings | −$35.3M | — | — |
| Operating cash flow | −$15.0M | — | — |
What changed
Revenue was $192K in Q4 2024, down 66% year over year and down 23% from the previous quarter.
Operating costs exceeded revenue by $13.3M, an operating margin of -6932.8%. Total costs grew 64% against a revenue fall of 66%. The fastest-growing cost line was Research & development (+338%). The quarter ended with a net loss of $35.3M, after a profit of $23.0M the previous quarter. Net interest and other expense of $21.9M was the main reason.
Operating cash flow was −$15.0M. Non-cash charges added back $68K of depreciation and amortization and $2.9M of share-based compensation. Working capital and other items added $17.3M.
Questions
What was Avalo Therapeutics' revenue in the fourth quarter 2024?
Avalo Therapeutics (AVTX) reported revenue of $192K for the fourth quarter 2024 (Q4 2024), -66% from a year earlier and -23% from the quarter before.
Source: Avalo Therapeutics 10-K on SEC EDGAR.